Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 9, 1999, Pages 2226-2233

  Gowri, Maya S ^a   Van Der Westhuyzen, Deneys R ^a   Bridges, Susan R ^a   Anderson, James W ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Diabetes; HDL; Hypertriglyceridemia; Oxidized LDL

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DIET RESTRICTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032877558     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.9.2226     Document Type: Article

References (40)

1. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12: 647-656.
2. Fontbonne A, Eschwege E, Cambien F, Richard J-L, Ducimetiere P, Thibult N, Warnet J-M, Claude J-R, Rosselin G-E. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-304.
3. Cavallero E, Dachet C, Neufcour D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism. 1994;43:270-278.
4. Bagdade JD, Buchanan WE, Kuusi T, Taskinen MR. Persistent abnormalities in lipoprotein composition in noninsulin-dependent diabetes after intensive insulin therapy. Arteriosclerosis. 1990;10:232-239.
5. Howard BV, Xiaoren P, Harper I, Foley JE, Cheung MC, Taskinen M-R. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am J Med. 1986;79(suppl 3B):78-85.
6. Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Bassett ML, Bierman EL. Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes. 1982;31:126-131.
7. Taskinen M-R. Lipoprotein lipase in diabetes. Diabetes Metab Rev. 1987; 3:551-570.
8. Barter PJ, Jones ME. Kinetic studies of the transfer of esterified cholesterol between human plasma low and high density lipoproteins. J Lipid Res. 1980;21:238-249.
9. Tall A, Sammett D, Granot E. Mechanisms of enhanced cholesteryl ester transfer from high density lipoproteins to apolipoprotein B-containing lipoproteins during alimentary lipemia. J Clin Invest. 1986;77: 1163-1172.
10. Bagdade JD, Lane JT, Subaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus. Arteriosclerosis. 1993;104:69-77.
11. Sutherland WHF, Walker RJ, Barned NJL, Pratt H, Tillman HC. The effect of acute hyperinsulinemia on plasma cholesteryl ester transfer protein activity in patients with non-insulin-dependent diabetes mellitus and healthy subjects. Metabolism. 1994;43:1362-1366.
12. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 1995;44:60-66.
13. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary heart disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
14. Parthasarathy S, Barnett J, Fong LG. High density lipoprotein inhibits the oxidative modification of low density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
15. Mackness MI, Abbott C, Arrol S, Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294:829-843.
16. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95: 774-782.
17. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
18. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low density lipoprotein. Trans Assoc Am Phys. 1993;105:44-63.
19. Cavallero E, Brites F, Delfly B, Nicolaiew N, Decossin C, De Geitere C, Fruchart J-C, Wikinski R, Jacotot B, Castro G. Abnormal reverse cholesterol transport in controlled type II diabetic patients: studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol. 1995; 15:2130-2135.
20. Mackness MI, Durrington PN. Lipoprotein separation and analysis for clinical studies. In: Converse CA, Skinner ER, eds. Lipoprotein Analysis: A Practical Approach. New York, NY: Oxford University Press; 1992:1-42.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
22. Strachan AF, de Beer FC, Van der Westhuyzen DR, Coetzee GA. Identification of three isoforms pattern of human serum amyloid A protein. Biochem J. 1988;250:203-207.
23. Godenir NL, Jeenah MS, Coetzee GA, Van der Westhuyzen DR, Strachan AF, de Beer FC. Standardization of the quantitation of serum amyloid A protein (SAA) in human serum. J Immunol Methods. 1985;83:217-225.
24. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
25. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities. Drug Metab Dispos. 1991;19:100-106.
26. Steinbrecher UP, Pritchard PH. Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res. 1989;30:305-315.
27. Via DP, Pons L, Dennison DK, Fanslow AE, Bernini F. Induction of acetyl-LDL receptor activity by phorbol ester in human monocyte cell line THP-1. J Lipid Res. 1989;30:1515-1524.
28. Leake DS, Rankin SM. The oxidative modification of low-density lipoproteins by macrophages. Biochem J. 1990;270:741-748.
29. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
30. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res. 1968;9:693-700.
31. Wilkinson L. SYSTAT, the System for Statistics, Evanston, Ill: SYSTAT Inc: 1987.
32. Tall AR, Blum CB, Forester GP, Nelson CA. Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat. J Biol Chem. 1982;257:198-207.
33. Patsch JR, Karlin JB, Scott L, Smith L, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci U S A. 1983;80: 1449-1453.
34. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride determines structure-composition in low and high density lipoproteins. Arteriosclerosis. 1984;4:225-231.
35. Durlach V, Attia N, Zahouani A, Leutenegger M, Girard-Globa A. Postprandial cholesteryl ester transfer and high density lipoprotein composition in normotriglyceridemic non-insulin-dependent diabetes patients. Atherosclerosis. 1996;120:155-165.
36. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJM. Effect of treatment with a hydroxymethylglutaryl coenzyme a reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes. 1995;44:460-465.
37. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:1812-1818.
38. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
39. McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol. 1995;15:1599-1606.
40. Dentan C, Lesnik P, Chapman MJ, Ninio E. PAF-acether-degrading acetylhydrolase in plasma LDL is inactivated by copper- and cell-mediated oxidation. Arterioscler Thromb. 1994;14:353-360.